Streetbeat News

Revenues

BLDP

Ballard Power Systems announced orders for 70 hydrogen fuel cell engines from Wrightbus for delivery in 2024, with the buses expected to enter service in 2025. This marks a significant step in the deployment of hydrogen-powered buses in the UK and Europe, aiming to decarbonize public transit.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:36 pm

CMCM

EGIO

RCAT

VISL

As of April 16, 2024, Red Cat Holdings, Inc. (RCAT), Edgio, Inc. (EGIO), Vislink Technologies, Inc. (VISL), and Cheetah Mobile Inc. (CMCM) are identified as overbought tech stocks based on their RSI values, indicating potential short-term performance concerns. RCAT, EGIO, and VISL have shown significant gains following positive financial updates, while CMCM experienced a jump despite a decline in FY sales.

Portfolio Pulse from Avi Kapoor

April 16, 2024 | 12:35 pm

SPY

USA housing starts in March were reported at 1.321 million, significantly below the estimated 1.480 million and the previous month's 1.549 million. This indicates a slowdown in the housing market.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:31 pm

SPY

The Building Permits (MoM) for March showed a decrease of 4.3%, indicating a slowdown in the construction sector. This data could have implications for the broader economy and potentially affect market sentiment.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:30 pm

AMRX

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) launched PEMRYDI RTU, the first ready-to-use pemetrexed injectable for non-squamous non-small cell lung cancer and malignant pleural mesothelioma, eliminating the need for reconstitution, dilution, or refrigeration. This launch is part of Amneal's strategy to release two to three branded oncology 505(b)(2) products annually, starting in 2024. PEMRYDI RTU has a unique J-Code (J9324) for reimbursement and is available in two vial sizes. It's indicated for use with pembrolizumab and platinum chemotherapy or cisplatin. U.S. annual sales for pemetrexed were $287 million for the 12 months ending February 2024.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:16 pm

PACB

PacBio announced preliminary Q1 revenue of $38.8M, significantly below the estimated $50.27M. The company also projected 2024 revenue to be between $170M-$200M, which is lower than the expected $238.67M.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:07 pm

BNZI

ENOV

LDI

Banzai International, Inc. (NASDAQ:BNZI) reported a 46% increase in customer growth in Q1 2024, adding over 580 customers, driven by its Demio and Reach platforms. New clients include Cisco, LoanDepot (NYSE:LDI), and Enovis (NYSE:ENOV). The company is also exploring acquisitions of Boast, IGLeads, and Cliently, and launched Demio AI Moderator, enhancing its marketing technology offerings.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:05 pm

BOOT

Analysts have updated their ratings on Boot Barn Holdings (NYSE:BOOT), with a mix of bullish to bearish sentiments. The average 12-month price target is now $94.25, up 6.2% from the previous $88.75. Recent actions include both raised and lowered price targets by analysts from Piper Sandler, Baird, and B. Riley Securities. Boot Barn's financials show positive revenue growth but below-average ROE, with strong net margin and ROA, and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 12:02 pm

KLAC

Analyst ratings for KLA (NASDAQ:KLAC) show a mix of bullish and bearish perspectives with a recent positive shift in the 12-month price target to $685.22, up 8.15% from $633.57. The company, a major player in semiconductor wafer fabrication equipment, faces a -16.66% revenue decline but maintains strong profitability indicators such as a net margin of 23.43% and ROE of 19.31%. Analysts' actions and price target adjustments reflect evolving market conditions and KLA's performance.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 12:01 pm

HON

Analysts have mixed views on Honeywell Intl (NASDAQ:HON), with ratings ranging from bullish to bearish over the last quarter. The average 12-month price target is $225.2, reflecting a slight increase from the previous target. Recent actions by analysts include adjustments to ratings and price targets, with some raising and others lowering their expectations based on Honeywell's market performance and financial indicators. Honeywell, a global multi-industry company, has shown significant market capitalization, revenue growth, and strong financial performance metrics such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 12:01 pm